Results 61 to 70 of about 36,144 (247)

Reduction Process of Pt(IV) Complexes With Axial Acetato Ligands by Ascorbic Acid; Comparison of Experimental and Computational Tools

open access: yesChemistry – A European Journal, EarlyView.
Comparison of experimental and calculated rate constants for reduction of selected Pt(IV) complexes by ascorbic acid (AA) in water solution at pH = 7. ABSTRACT In the present work, the reduction mechanism of several Pt(IV) complexes bearing two axial acetato ligands by ascorbic acid (AA) was investigated.
Ondřej Tichý   +3 more
wiley   +1 more source

New QSAR Models to Predict Human Transthyretin Disruption by Per- and Polyfluoroalkyl Substances (PFAS): Development and Application

open access: yesToxics
Per- and polyfluoroalkyl substances (PFAS) are of concern because of their potential thyroid hormone system disruption by binding to human transthyretin (hTTR). However, the amount of experimental data is scarce.
Marco Evangelista   +2 more
doaj   +1 more source

Pediatric Developmental Safety Assessment: Are We Ready for the Next Thalidomide?

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pediatric drug development has achieved remarkable success in the last 20 years with over 1,000 products studied in pediatric patients. This success has been driven in part by an increased understanding of pediatric disease processes. The aspect that has been largely overlooked is the potential adverse effect of new drugs on pediatric developmental ...
Gilbert J. Burckart   +6 more
wiley   +1 more source

Zenodo copy of generic-qsar-py-utils (version 0.1)

open access: yes, 2016
<p>This is a Zenodo copy of generic-qsar-py-utils (version 0.1), for which the latest version can be found here: https://github.com/RichardLMR/generic-qsar-py-utils</p ...
Richard L. Marchese Robinson (5273902)   +1 more
core   +1 more source

Advances in New Approach Methodologies at FDA's Division of Applied Regulatory Science

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
New Approach Methodologies (NAMs) represent a paradigm shift in drug development and regulatory science, offering human‐relevant alternatives to traditional preclinical models. This mini‐review highlights recent advances in NAM development, validation, and regulatory application from FDA's Division of Applied Regulatory Science (DARS).
Ksenia Blinova   +9 more
wiley   +1 more source

Artificial intelligence in preclinical epilepsy research: Current state, potential, and challenges

open access: yesEpilepsia Open, EarlyView.
Abstract Preclinical translational epilepsy research uses animal models to better understand the mechanisms underlying epilepsy and its comorbidities, as well as to analyze and develop potential treatments that may mitigate this neurological disorder and its associated conditions. Artificial intelligence (AI) has emerged as a transformative tool across
Jesús Servando Medel‐Matus   +7 more
wiley   +1 more source

Classical and hologram QSAR studies on a series of inhibitors of trypanosomatid Glyceraldehyde-3-Phosphate Dehydrogenase

open access: yes, 2008
Leishmaniasis and trypanosomiasis are major causes of morbidity and mortality in both tropical and subtropical regions of the world. The current available drugs are limited, ineffective, and require long treatment regimens.
GUIDO, Rafael Victório Carvalho   +4 more
core   +1 more source

Citrus Essential Oils in Food Safety and Health: Advances in AI‐Assisted Authentication, Antimicrobial Applications, Sustainable Extraction, and Regulatory Translation

open access: yesFood Safety and Health, EarlyView.
Citrus essential oils combine sustainable extraction, AI‐assisted authentication, multi‐omics profiling, antimicrobial activity, and regulatory safety to enhance food quality, detect adulteration, and promote consumer health, and support intelligent, sustainable food systems through innovative industrial applications and circular bioeconomy strategies.
Md. Hassan Bin Nabi   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy